AnaptysBio (ANAB) PT Raised to $70 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts ANAB Hot Sheet
Price: $48.64 -3.68%
Rating Summary:
13 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
13 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
Wedbush analyst David Nierengarten raised the price target on AnaptysBio (NASDAQ: ANAB) to $70.00 (from $45.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- Baxter International (BAX) PT Lowered to $25 at Jefferies
- Establishment Labs Inc. (ESTA) PT Lowered to $93 at BTIG
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
